Have you seen the latest news and insights on Cystic Fibrosis News Today?

Cystic Fibrosis Weekly Update Contents: When Comparing Yourself to Others Makes You the Worst FDA Efforts to Bring Patients into Treatment Decisions Focus of NORD Webinar It’s Time to Live Slowly Orkambi Therapy Reduces Hepatic Steatosis in CF Patients, Study Shows  When Comparing Yourself to Others Makes You the Worst Feb 11, 2020 03:00 pm | Bailey Vincent I compare myself to other people. I shouldn’t, but I do. Sometimes, other people seem nervous to compare themselves to me. “I don’t want to sound like I’m complaining about my health to you” is a regularity, and I never stop appreciating that sensitivity. We have all known that person who kvetches and rants about […] The post When Comparing Yourself to Others Makes You the Worst appeared first on Cystic Fibrosis News Today. Read More FDA Efforts to Bring Patients into Treatment Decisions Focus of NORD Webinar Feb 11, 2020 11:51 am | Hawken Miller The U.S. Food and Drug Administration (FDA), a vast government bureaucracy, employs about 17,500 people and had a budget of $5.7 billion in 2019. Yet even with its enormous resources, the FDA these days relies more and more on patients to provide feedback on therapy development, set regulatory priorities, and contribute to patient-reported outcomes. Starting […] The post FDA Efforts to Bring Patients into Treatment Decisions Focus of NORD Webinar appeared first on Cystic Fibrosis News Today. Read More It’s Time to Live Slowly Feb 11, 2020 09:00 am | Brad Dell I haven’t tasted much energy over the past month. Thanks to steroid withdrawal, I spend most of my time near home. It’s not all that bad, honestly, to sit around and do nothing. “Doing nothing” can be productive. I didn’t always feel that. Back in my pre-transplant days, I got a lot of use outta […] The post It’s Time to Live Slowly appeared first on Cystic Fibrosis News Today. Read More Orkambi Therapy Reduces Hepatic Steatosis in CF Patients, Study Shows  Feb 11, 2020 07:00 am | Steve Bryson PhD People with cystic fibrosis (CF) who were treated with Orkambi (lumacaftor/ivacaftor) have significantly less accumulation of fat in the liver — a condition known as hepatic steatosis — which is often associated with CF, a study showed.  While hepatic steatosis is common in those with type 2 diabetes, there was no link found between CF-related diabetes […] The post Orkambi Therapy Reduces Hepatic Steatosis in CF Patients, Study Shows  appeared first on Cystic Fibrosis News Today. Read More Recent News Exploring Autonomy and Paternalism in the Doctor-patient Relationship Higher Blood Levels of Tiny Molecule May Be Linked to How CF Affects Girls, Study Suggests With Post-Brexit Move to Amsterdam Complete, EMA Renews Rare Disease Focus Research Sets Out to Identify Mechanisms of Dormant, Antibiotic-resistant Bacteria Poor Gut Microbiota in Infants with CF Linked to Stunted Growth in 1st Year of Life, Study Suggests